Advertisement

Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL

Paolo Strati, Koichi Takahashi, Christine B. Peterson, Michael J. Keating, Philip A. Thompson, Naval G. Daver, Nitin Jain, Jan A. Burger, Zeev Estrov, Susan M. O'Brien, Hagop M. Kantarjian, William G. Wierda, P. Andrew Futreal and Alessandra Ferrajoli

Article Information

Citation 
vol. 3 no. 9 1533-1539
PubMed 

Print ISSN 
Online ISSN 
History 
  • Submitted January 9, 2019
  • Accepted March 26, 2019
  • Published online May 10, 2019.


Contributors 
  • Paolo Strati, 1Department of Leukemia,
  • Koichi Takahashi, 1Department of Leukemia,2Department of Genomic Medicine, and
  • Christine B. Peterson, 3Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX
  • Michael J. Keating, 1Department of Leukemia,
  • Philip A. Thompson, 1Department of Leukemia,
  • Naval G. Daver, 1Department of Leukemia,
  • Nitin Jain, 1Department of Leukemia,
  • Jan A. Burger, 1Department of Leukemia,
  • Zeev Estrov, 1Department of Leukemia,
  • Susan M. O'Brien, 1Department of Leukemia,
  • Hagop M. Kantarjian, 1Department of Leukemia,
  • William G. Wierda, 1Department of Leukemia,
  • P. Andrew Futreal, 2Department of Genomic Medicine, and
  • Alessandra Ferrajoli, 1Department of Leukemia,

Altmetric.com Statistics

The Altmetric score is a weighted count of online attention designed to reflect the volume and reach of online engagement surrounding an individual research output